Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.41−0.48 (-2.19%)
Close on Nov 16, 2026Market cap $2.03BP/E –Yield –
Replimune net income
Net income is the profit left for shareholders after every expense, interest and tax.
Replimune's net income for the twelve months ending Sep 30, 2026 was -$271.03M. For fiscal 2026 it was -$313.94M. The highest annual figure on record is -$7.70M in fiscal 2017.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$313.94M | – |
| FY2025 | Mar 31, 2025 | -$247.30M | – |
| FY2024 | Mar 31, 2024 | -$215.79M | – |
| FY2023 | Mar 31, 2023 | -$174.28M | – |
| FY2022 | Mar 31, 2022 | -$118.04M | – |
| FY2021 | Mar 31, 2021 | -$80.87M | – |
| FY2020 | Mar 31, 2020 | -$52.63M | – |
| FY2019 | Mar 31, 2019 | -$30.83M | – |
| FY2018 | Mar 31, 2018 | -$19.70M | – |
| FY2017 | Mar 31, 2017 | -$7.70M | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | -$57.12M | – |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$69.77M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$73.22M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$70.93M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$83.10M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$86.69M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$74.13M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$66.34M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$53.06M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$53.77M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$55.08M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$51.12M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$60.04M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$49.56M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$49.24M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$39.69M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$43.10M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$42.25M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$31.70M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$29.67M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$29.36M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$27.31M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$21.50M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$21.78M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$20.10M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$17.49M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$15.79M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$16.19M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$11.14M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$9.51M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$6.66M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$7.67M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$6.46M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$10.04M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$7.14M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$4.35M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$4.66M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$3.55M | – |
See a number that looks wrong?